Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance

Journal of Molecular Biology

Volumn 243, Issue 3, 1994, Pages 369-387

  Tantillo, Chris ^a   Ding, Jianping ^a   Jacobo Molina, Alfredo ^a,e   Nanni, Raymond G ^a,f   Boyer, Paul L ^b   Hughes, Stephen H ^b   Pauwels, Rudi ^c,g   Andries, Koen ^d   Janssen, Paul A J ^d   Arnold, Edward ^a  

^a RUTGERS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^f LOS ALAMOS NATIONAL LABORATORY   (United States)

^g TIBOTEC BVBA   (Belgium)

Author keywords

Drug resistance; Non nucleoside inhibitor; Nucleoside analog inhibitor; Reverse transcriptase; Structure based drug design

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APA R90385; BHAP U 90152S; DIDANOSINE; ENZYME INHIBITOR; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; TIBO R86183; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

DRUG BINDING SITE; DRUG DESIGN; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; REVIEW; VIRUS MUTATION;

EID: 0028172345     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1994.1665     Document Type: Review

References (92)

1. Althaus, I. W., Chou, J. J., Gonzalez, A. J., Deibel, M. R., Chou, K.-C., Kezdy, F. J., Romero, D. L., Aristoff, P. A., Tarpley, W. G. & Reusser, F. (1993). Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J. Biol. Chem. 268, 6119-6124.
2. Arnold, E., Jacobo-Molina, A., Nanni, R. G., Williams, R. L., Lu, X., Ding, J., Clark, A. D., Jr, Zhang, A., Ferris, A. L., Clark, P., Hizi, A. & Hughes, S. H. (1992). Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations. Nature (London), 357, 85-89.
3. Bacolla, A., Shih, C.-K., Rose, J. M., Piras, G., Warren, T. C., Grygon, C. A., Ingraham, R. H., Cousins, R. C., Greenwood, D. J., Richman, D., Cheng, Y.-C. & Griffin, J. A. (1993). Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. J. Biol. Chem. 268, 16571-16577.
4. Balzarini, J., Perez-Perez, M.-J., San-Felix, A., Camarasa, M.-J., Bathurst, I. C., Barr, P. J. & De Clercq, E. (1992a). Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analog [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide)thymine (TSAO-T). J. Biol. Chem. 267, 11831-11838.
5. Balzarini, J., Perez-Perez, M.-J., San-Felix, A., Schols, D., Perno, C.-F., Vandamme, A.-M., Camarasa, M. J. & De Clercq, E. (1992b). 2′,5′-Bis-O-(tertbutyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Nat. Acad. Sci., U.S.A. 89, 4392-4396.
6. Balzarini, J., Karlsson, A., Perez-Perez, M.-J., Camarasa, M.-J. & De Clercq, E. (1993a). Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology, 196, 576-585.
7. Balzarini, J., Karlsson, A., Perez-Perez, M.-J., Vrang, L., Walbers, J., Oberg, B., Vandamme, A.-M., Camarasa, M.-J. & De Clercq, E. (1993b). HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology, 192, 246-253.
8. Balzarini, J., Karlsson, A. & De Clercq, E. (1993c). Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]6-(phenylthio)thymine derivatives. Mol. Pharmacol. 44, 694-701.
9. Boyer, P. L., Ferris, A. L. & Hughes, S. H. (1992). Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 66, 1031-1039.
10. Boyer, P. L., Currens, M. J., McMahon, J. B., Boyd, M. R. & Hughes, S. H. (1993). Analysis of non-nucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67, 2412-2420.
11. Boyer, P. L., Ding, J., Arnold, E., Hughes, S. H. (1994a). Drug resistance of human immunodeficiency virus type 1 reverse transcriptase: subunit specificity of mutations that confer resistance to non-nucleoside inhibitors. Antimicrob. Agents Chemother. 38, 1909-1914.
12. Boyer, P. L., Ferris, A. L., Clark, P., Whitmer, J., Frank, P., Tantillo, C., Arnold, E. & Hughes, S. H. (1994b). Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. J. Mol. Biol. 243, 472-483.
13. Boyer, P. L., Tantillo, C., Jacobo-Molina, A., Nanni, R. G., Ding, J., Arnold, E. & Hughes, S. H. (1994c). The sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Nat. Acad. Sci., U.S.A. 91, 4882-4886.
14. Byrnes, V. W., Sardana, V. V., Schleif, W. A., Condra, J. H., Waterbury, J. A., Wolfgang, J. A., Long, W. J., Schneider, C. L., Schlabach, A. J., Wolanski, B. S., Graham, D. J., Gotlib, L., Rhodes, A., Titus, D. L., Roth, E., Blahy, O. M., Quintero, J. C., Staszewski, S. & Emini, E. A. (1993). Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to non-nucleoside inhibitors. Antimicrob. Agents Chemother. 37, 1576-1579.
15. Carroll, S. S., Olsen, D. B., Bennett, C. D., Gotlib, L., Graham, D. J., Condra, J. H., Stern, A. M., Shafer, J. A. & Kuo, L. C. (1993). Inhibition of HIV-1 reverse transcriptase by pyridinone derivatives. J. Biol. Chem. 268, 276-281.
16. Condra, J. H., Emini, E. A., Gotlib, L., Graham, D. J., Schlabach, A. J., Wolfgang, J. A., Colonno, R. J. & Sardana, V. V. (1992). Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse non-nucleoside inhibitors. Antimicrob. Agents Chemother. 36, 1441-1446.
17. Debyser, Z., Pauwels, R., Andries, K., Desmyter, J., Kukla, M., Janssen, P. A. J. & De Clercq, E. (1991). An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives. Proc. Nat. Acad. Sci., U.S.A. 88, 1451-1455.
18. De Vreese, K., Debyser, Z., Vandamme, A.-M., Pauwels, R., Desmyter, J., De Clercq, E. & Jozef, A. (1992). Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology, 188, 900-904.
19. Demeter, L., Resnick, L., Nawaz, T., Timpone, J. G., Jr, Batts, D. & Reichman, R. C. (1993). Phenotypic and genotypic analysis of ateviridine (ATV) susceptibility of HIV-1 isolates obtained from patients receiving ATV monotherapy in a phase 1 clinical trial (ACTG 187): comparison to patients receiving combination therapy with ATV and zidovudine. Third Workshop on Viral Resistance, Gaithersburg, MD, U.S.A.
20. Dong, Q., Copeland, W. C. & Wang, T. S.-F. (1993). Mutational studies of human DNA polymerase α. J. Biol. Chem. 268, 24163-24174.
21. Dueweke, T. J., Kezdy, F. J., Waszak, G. A., Deibel, M. R., Jr & Tarpley, W. G. (1992). The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 267, 27-30.
22. Dueweke, T. J., Pushkarskaya, T., Poppe, S. M., Swaney, S. M., Zhao, J. Q., Chen, I. S. Y., Stevenson, M. & Tarpley, W. G. (1993). A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors. Proc. Nat. Acad. Sci., U.S.A. 90, 4713-4717.
23. Fitzgibbon, J. E., Howell, R. M., Haberzettl, C. A., Sperber, S. J., Gocke, D. J. & Dubin, D. T. (1992). Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36, 153-157.
24. Frank, K. B., Noll, G. J., Connell, E. V. & Sim, I. S. (1991). Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidaxo[4,5,1,jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, R82150. J. Biol. Chem. 266, 14232-14236.
25. Goff, S. P. (1990). Retroviral reverse transcriptase: synthesis, structure, and function. J. Acq. Immune Defic. Syndr. 3, 817-831.
26. Goldman, M. E., Nunberg, J. H., O'Brien, J. A., Quintero, J. C., Schleif, W. A., Freund, K. F., Gaul, S. L., Saari, W. S., Wai, J. S., Hoffman, J. M., Anderson, P. S., Hupe, D. J., Emini, E. A. & Stern, A. M. (1991). Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Nat. Acad. Sci., U.S.A. 88, 6863-6867.
27. Goldman, M. E., O'Brien, J. A., Ruffing, T. L., Schleif, W. A., Sardana, V. V., Bynes, V. W., Condra, J. H., Hoffman, J. M. & Emini, E. A. (1993). A non-nucleoside reverse transcriptase inhibitor active on human immunodeficiency type 1 isolates resistant to related inhibitors. Antimicrob. Agents Chemother. 37, 947-949.
28. Goody, R. S., Muller, B. & Restle, T. (1991). Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Letters, 291, 1-5.
29. Gu, Z., Gao, Q., Li, X., Parniak, M. A. & Wainberg, M. A. (1992). Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66, 7128-7135.
30. Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M. A., Goldberg, E., Cameron, J. & Wainberg, M. A. (1994). Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38, 275-281.
31. Havlir, D., Murphy, R., Saag, M., Kaul, I., Johnson, V. & Richman, D. D. (1993). Nevirapine: further dose escalation of monotherapy (600 mg/daily) and combination therapy with zidovudine. The First National Conference on Human Retroviruses and Related Infections, American Society for Microbiology, Washington, D.C.
32. Herdewijn, P. A. M. M. (1992). Novel nucleoside strategies for anti-HIV and anti-HSV therapy. Antiviral Res. 19, 1-14.
33. Hizi, A., Tal, R., Shaharabany, M., Currens, M. J., Boyd, M. R., Hughes, S. H. & McMahon, J. B. (1993). Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by non-nucleoside inhibitors. Antimicrob. Agents Chemother. 37, 1037-1042.
34. Hsieh, J., Zinnen, S. & Modrich, P. (1993). Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 268, 24607-24613.
35. Jacobo-Molina, A. & Arnold, E. (1991). HIV reverse transcriptase structure-function relationships. Biochemistry, 30, 6351-6361.
36. Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Jr, Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., Hizi, A., Hughes, S. H. & Arnold, E. (1993). Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Nat. Acad. Sci., U.S.A. 90, 6320-6324.
37. Japour, A. J., Chatis, P. A., Eignerauch, H. A. & Crumpacker, C. S. (1991). Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridization. Proc. Nat. Acad. Sci., U.S.A. 88, 3092-3096.
38. Johnson, M. S., McClure, M. A., Feng, D., Gray, J. & Doolittle, R. F. (1986). Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc. Nat. Acad. Sci., U.S.A. 83, 7648-7652.
39. Johnston, M. I. & Hoth, D. F. (1993). Present status and future prospects for HIV therapies. Science, 260, 1286-1293.
40. Kashman, Y., Gustafson, K. R., Fuller, R. W., Cardellina, J. H., II, McMahon, J. B., Currens, M. J., Buckheit, R. W. J., Hughes, S. H., Cragg, G. M. & Boyd, M. R. (1992). The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum langericum. J. Med. Chem. 35, 2735-2743.
41. Kati, W. M., Johnson, K. A., Jerva, L. F. & Anderson, K. S. (1992). Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267, 25988-25997.
42. Kellam, P., Boucher, C. A. & Larder, B. A. (1992). Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Nat. Acad. Sci., U.S.A. 89, 1934-1938.
43. Kleim, J.-P., Bender, R., Billhardt, U.-M., Meichsner, C., Riess, G., Rosner, M., Winkler, I. & Paessens, A. (1993). Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37, 1659-1664.
44. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. (1992). Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-1790.
45. Kopp, E. B., Miglietta, J. J., Shrutkowski, A. G., Shih, C.-K., Grob, P. M. & Skoog, M. T. (1991). Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template. Nucl. Acids Res. 19, 3035-3039.
46. Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R. & Ferrin, T. E. (1982). A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161, 269-288.
47. Lacey, S. F., Reardon, J. E., Furfine, E. S., Kunkel, T. A., Bebenek, K., Eckert, K. A., Kemp, S. D. & Larder, B. A. (1992). Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem. 267, 15789-15794.
48. Larder, B. A. (1992). 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36, 2664-2669.
49. Larder, B. A. (1993). Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance. In Reverse Transcriptase (Skalka, A. M. & Goff, S. P., eds), pp. 205-222, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
50. Larder, B. A. & Kemp, S. D. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science, 246, 1155-1158.
51. Larder, B. A., Kemp, S. D. & Purifoy, D. J. M. (1989a). Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Nat. Acad. Sci., U.S.A. 86, 4803-4807.
52. Larder, B. A., Darby, G. & Richman, D. D. (1989b). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science, 243, 1731-1734.
53. Larder, B. A., Coates, K. E. & Kemp, S. D. (1991). Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65, 5232-5236.
54. Larder, B. A., Purifoy, D. J. M., Powell, K. L. & Darby, G. (1987). Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature (London), 327, 716-717.
55. Lee, B. & Richards, F. M. (1971). Interpretation of protein structures: estimation of static accessibilit. J. Mol. Biol. 55, 379-400.
56. Le Grice, S. F. J. (1993). Human immunodeficiency virus reverse transcriptase. In Reverse Transcriptase (Skalka, A. M. & Goff, S. P., eds), pp. 163-191, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
57. Ma, Q.-F., Bathurst, I. C., Barr, P. J. & Kenyon, G. L. (1992). The observed inhibitory potency of 3′-azido-3′-deoxythymidine 5′-triphosphate for HIV-1 reverse transcriptase depends on the length of the poly(rA) region of the template. Biochemistry, 31, 1375-1379.
58. Martin, J. L., Wilson, J. E., Haynes, R. L. & Furman, P. A. (1993). Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. Nat. Acad. Sci., U.S.A. 90, 6135-6139.
59. Mellors, J. W., Dutschman, G. E., Im, G.-J., Tramontano, E., Winkler, S. R. & Cheng, Y.-C. (1992). Rapid emergence of HIV-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Antiviral Res. 17 S1, 48.
60. Mellors, J. W., Im, C. J., Tramontano, E., Winkler, S. R., Medina, D. J., Dutschman, G. E., Bazmi, H. Z., Piras, G., Gonzalez, C. J. & Cheng, Y.-C. (1993). A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk]11, 4] benzodiazepin-2(1H)-thione (TIBO R82150). Mol. Pharmacol. 43, 11-16.
61. Merluzzi, V. J., Hargrave, K. D., Labadia, M., Grozinger, K., Skoog, M., Wu, J. C., Shih, C.-K., Eckner, K., Hattox, S., Adams, J., Rosenthal, A. S., Faanes, R., Eckner, R. J., Koup, R. A. & Sullivan, J. L. (1990). Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science, 250, 1411-1413.
62. Miyasaka, T., Tanaka, H., Baba, M., Hayakawa, H., Walker, R. T., Balzarini, J. & De Clercq, E. (1989). A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32, 2507-2509.
63. Nanni, R. G., Ding, J., Jacobo-Molina, A., Hughes, S. H. & Arnold, E. (1993). Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect. Drug Discovery Design, 1, 129-150.
64. Nicholls, A. (1992). GRASP: Graphical Representation and Analysis of Surface Properties. Columbia University, New York.
65. Nunberg, J. H., Schleif, W. A., Boots, E. J., O'Brien, J. A., Quintero, J. C., Hoffman, J. M., Emini, E. A. & Goldman, M. E. (1991). Viral resistance to human immunodeficiency virus type I-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65, 4887-4892.
66. Pantaleo, G., Graziosi, C. & Fauci, A. S. (1993). The immunopathogenesis of human immunodeficiency virus infection. N. Engl. J. Med. 328, 327-335.
67. Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M. J., Breslin, H. J., Raeymaeckers, A., Van Gelder, J., Woestenborghs, R., Heykants, J., Schellekens, K., Janssen, M. A. C., De Clercq, E. & Janssen, P. A. J. (1990). Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (London), 343, 470-474.
68. Pauwels, R., Andries, K., Debyser, Z., Van Dale, P., Schols, D., Stoffels, P., De Vreese, K., Woestenborghs, R., Vandamme, A.-M., Janssen, C. G. M., Anné, J., Gauwenbergh, G., Desmyter, J., Heykants, J., Janssen, M. A. C., DeClercq, E. & Janssen, P. A. J. (1993). Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Nat. Acad. Sci., U.S.A. 90, 1711-1715.
69. Poch, O., Sauvaget, I., Delarue, M. & Tordo, N. (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8, 3867-3874.
70. Prasad, V. R., Lowy, T., Santos, T. D. L., Chiang, L. & Goff, S. P. (1991). Isolation and characterization of a dideoxyguanosinetriphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase. Proc. Nat. Acad. Sci., U.S.A. 88, 11363-11367.
71. Richman, D. D. (1993). Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37, 1207-1213.
72. Richman, D., Shih, C. K., Lowy, I., Rose, J., Prodanovich, P., Goff, S. & Griffin, J. (1991). Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Nat. Acad. Sci., U.S.A. 88, 11241-11245.
73. Richman, D. D. and the ACTG 164/168 Study Team. (1993). Nevirapine resistance during clinical trials. Second International HIV-1 Drug Resistance Workshop, Noordwijk, The Netherlands.
74. Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A., Sullivan, J., Cheeseman, S., Barringer, K., Pauletti, D., Shih, C.-K., Myers, M. & Griffin, J. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68, 1660-1666.
75. Romero, D. L., Busso, M., Tan, C.-K., Reusser, F., Palmer, J. R., Poppe, S. M., Aristoff, P. A., Downey K. M., So, A. G., Resnick, L. & Tarpley, W. G. (1991). Non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Nat. Acad. Sci., U.S.A. 88, 8806-8810.
76. Saag, M. S., Sommadossi, J. P., Rainey, D., Myers, M., Cort, S., Hall, D., Robinson, S., Piatak, M., Lifson, J., Kappes, J. & Shaw, G. M. (1993). A pharmacokinetic and antiretroviral activity study of nevirapine in combination with zidovudine plus zalcitabine (ZDV/ ddC), zidovudine plus didanosine (ZDV/ddI), or didanosine (ddI) alone. The First National Conference on Human Retroviruses and Related Infections. The American Society for Microbiology, Washington, DC.
77. Sandström, E. & Oberg, B. (1993). Antiviral therapy in human immunodeficiency virus infections (part I). Drugs, 45, 488-508.
78. Sardana, V. V., Emini, E. A., Gotlib, L., Graham, D. J., Lineberger, D. W., Long, W. J., Schlabach, A. J., Wolfgang, J. A. & Condra, J. H. (1992). Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple non-nucleoside inhibitors. J. Biol. Chem. 267, 17526-17530.
79. Saunders, J. & Storer, R. (1992). New developments in RT inhibitors. Drug News Perspect. 5, 153-169.
80. Schinazi, R. F. (1993). Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspect. Drug Discovery Design, 1, 151-180.
81. Schinazi, R., Larder, B. & Mellors, J. (1994). Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News, 2, 72-75.
82. Shih, C.-K., Rose, J. M., Hansen, G. L., Wu, J. C., Bacolla, A. & Griffin, J. A. (1991). Chimeric human immunodeficiency virus type I/type 2 reverse transcriptases display reversed sensitivity to non-nucleoside analog inhibitors. Proc. Nat. Acad. Sci., U.S.A. 88, 9878-9882.
83. Song, Q., Yang, G., Goff, S. P. &, Prasad, V. R. (1992). Mutagenesis of the Glu-89 residue in human immunodeficiency virus type 1 (HIV-1) and HIV-2 reverse transcriptases: effects on nucleoside analog resistance. J. Virol. 66, 7568-7571.
84. St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D. & Larder, B. A. (1991). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science, 253, 1557-1559.
85. Strair, R. K. & Mellors, J. W. (1993). Resistance of human immunodeficiency virus-1 to antiretroviral drugs. AIDS Updates, 6, 1-14.
86. Taylor, E. W., Van Roey, P., Schinazi, R. F. & Chu, C. K. (1990). A stereochemical rationale for the activity of anti-HIV nucleosides. Antiviral Chem. Chemother. 1, 163-173.
87. Taylor, P. B., Culp, J. S., Debouck, C., Johnson, R. K., Patil, A. D., Woolf, D. J., Brooks, I. & Hertzbeg, R. P. (1994). Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J. Biol. Chem. 269, 6325-6331.
88. Tisdale, M., Kemp, S. D., Parry, N. R. & Larder, B. A. (1993). Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Nat. Acad. Sci., U.S.A. 90, 5653-5656.
89. Tramontano, E. & Cheng, Y.-C. (1992). HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem. Pharmacol. 43, 1371-1376.
90. Vasudevachari, M. B., Battista, C., Lane, H. C., Psallidopoulos, M. C., Zhao, B., Cook, J., Palmer, J. R., Romero, D. L., Tarpley, W. G. & Salzman, N. P. (1992). Prevention of the spread of HIV-1 infection with non-nucleoside reverse transcriptase inhibitors. Virology, 190, 269-277.
91. Wu, J. C., Warren, T. C., Adams, J., Proudfoot, J., Skiles, J., Raghavan, P., Perry, C., Potocki, I., Farina, P. R. & Grob, P. M. (1991). A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry, 30, 2022-2026.
92. Young, S. D. (1993). Non-nucleoside inhibitors of HIV-1 reverse transcriptase. Perspect. Drug Discovery Design, 1, 181-192.